Terms: = Endocrine gland cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
270 results:
1. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract] [Full Text] [Related]
2. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic therapeutic strategies in pancreatic cancer.
Orlacchio A; Muzyka S; Gonda TA
Int Rev Cell Mol Biol; 2024; 383():1-40. PubMed ID: 38359967
[TBL] [Abstract] [Full Text] [Related]
4. Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study.
Gizaw M; Parkin DM; Stöter O; Bukirwa P; Seife E; Chesumbai G; Korir A; Liu B; Manraj SS; Nda G; Somdyala NIM; Kantelhardt EJ
Int J Cancer; 2024 Jun; 154(11):1911-1919. PubMed ID: 38339849
[TBL] [Abstract] [Full Text] [Related]
5. Closing the diagnostic gap: Liquid biopsy potential to transform ovarian cancer outcomes in sub-Saharan Africa.
Kokori E; Olatunji G; Ogieuhi IJ; Muogbo I; Isarinade D; Ukoaka B; Ajayi I; Ezenwoba C; Samuel O; Nurudeen-Busari H; Olawade DB; Aderinto N
Medicine (Baltimore); 2024 Feb; 103(5):e37154. PubMed ID: 38306573
[TBL] [Abstract] [Full Text] [Related]
6. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic cancer: A Systematic Review and Meta-Analysis.
Nichetti F; Rota S; Ambrosini P; Pircher C; Gusmaroli E; Droz Dit Busset M; Pusceddu S; Sposito C; Coppa J; Morano F; Pietrantonio F; Di Bartolomeo M; Mariani L; Mazzaferro V; de Braud F; Niger M
JAMA Netw Open; 2024 Jan; 7(1):e2350756. PubMed ID: 38190183
[TBL] [Abstract] [Full Text] [Related]
7. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
8. Long-term quality of life is better after laparoscopic compared to open pancreatoduodenectomy.
Dagorno C; Marique L; Korrel M; de Graaf N; Thouny C; Renault G; Ftériche FS; Aussilhou B; Maire F; Lévy P; Rebours V; Lesurtel M; Sauvanet A; Dokmak S
Surg Endosc; 2024 Feb; 38(2):769-779. PubMed ID: 38052888
[TBL] [Abstract] [Full Text] [Related]
9. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
10. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract] [Full Text] [Related]
11. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract] [Full Text] [Related]
13. Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Georgakopoulos A
Hell J Nucl Med; 2023; 26 Suppl():49-51. PubMed ID: 37658564
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian cancer Cells and a Transgenic Mouse Model of Ovarian cancer.
Huang Y; Fan Y; Zhao Z; Zhang X; Tucker K; Staley A; Suo H; Sun W; Shen X; Deng B; Pierce SR; West L; Yin Y; Emanuele MJ; Zhou C; Bae-Jump V
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569750
[TBL] [Abstract] [Full Text] [Related]
15. Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis.
Gong W; Yu R; Cao C; Fang Y; Zhao X; Gao Q
J Ovarian Res; 2023 Jul; 16(1):136. PubMed ID: 37430376
[TBL] [Abstract] [Full Text] [Related]
16. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
[TBL] [Abstract] [Full Text] [Related]
17. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.
Su YY; Chao YJ; Wang CJ; Liao TK; Su PJ; Huang CJ; Chiang NJ; Yu YT; Tsai HM; Chen LT; Shan YS
Int J Surg; 2023 Sep; 109(9):2614-2623. PubMed ID: 37300888
[TBL] [Abstract] [Full Text] [Related]
18. Characteristics and response cutoff of octreotide suppression test in thyrotrophin (TSH)-secreting pituitary adenomas.
Liu J; Yang Y; Duan L; Chai X; Zhu H; Deng K; Lian X; Yao Y
Clin Endocrinol (Oxf); 2023 Sep; 99(3):306-314. PubMed ID: 37144621
[TBL] [Abstract] [Full Text] [Related]
19. Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumors.
Mulders MCF; de Lussanet de la Sablonière QG; van Velthuysen MLF; Roes EM; Hofland J; de Herder WW
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140986
[TBL] [Abstract] [Full Text] [Related]
20. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs.
Chiloiro S; Giampietro A; Gessi M; Lauretti L; Mattogno PP; Cerroni L; Carlino A; De Alessandris QG; Olivi A; Rindi G; Pontecorvi A; De Marinis L; Doglietto F; Bianchi A
J Neuroendocrinol; 2023 Apr; 35(4):e13263. PubMed ID: 37078422
[TBL] [Abstract] [Full Text] [Related]
[Next]
